{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:53:25Z","timestamp":1791928405194,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Turkish Journal of Gastroenterology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44786-w","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T21:44:41Z","timestamp":1777758281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hepatic and metabolic effects of SGLT2 inhibitors in type 2 diabetes and MASLD assessed by metabolomic and lipidomic analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"Kenan","family":"Moral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevilay Erdo\u011fan","family":"Kablan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emirhan","family":"Nemutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halit Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahinur","family":"Cerit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Muhittin","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulden","family":"Bilican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Cindoruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarkan","family":"Karakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Vardar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergiz","family":"Ekmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"44786_CR1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","volume":"119","author":"C Grander","year":"2023","unstructured":"Grander, C., Grabherr, F. & Tilg, H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc. Res. 119, 1787\u20131798. https:\/\/doi.org\/10.1093\/cvr\/cvad095 (2023).","journal-title":"Cardiovasc. Res."},{"key":"44786_CR2","doi-asserted-by":"publisher","first-page":"108811","DOI":"10.1016\/j.pharmthera.2025.108811","volume":"268","author":"K Arvanitakis","year":"2025","unstructured":"Arvanitakis, K., Koufakis, T., Cholongitas, E., Francque, S. & Germanidis, G. Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy? Pharmacol. Ther. 268, 108811. https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108811 (2025).","journal-title":"Pharmacol. Ther."},{"key":"44786_CR3","doi-asserted-by":"publisher","unstructured":"Yanai, H., Hakoshima, M., Adachi, H. & Katsuyama, H. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22094416 (2021).","DOI":"10.3390\/ijms22094416"},{"key":"44786_CR4","doi-asserted-by":"publisher","first-page":"E492","DOI":"10.1152\/ajpendo.00401.2019","volume":"318","author":"K Tanaka","year":"2020","unstructured":"Tanaka, K. et al. Combined effect of canagliflozin and exercise training on high-fat diet-fed mice. Am. J. Physiol. Endocrinol. Metab. 318, E492\u2013e503. https:\/\/doi.org\/10.1152\/ajpendo.00401.2019 (2020).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"44786_CR5","doi-asserted-by":"publisher","unstructured":"Yabiku, K., Nakamoto, K. & Tsubakimoto, M. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. J. Diabetes Res. 2020 (1682904). https:\/\/doi.org\/10.1155\/2020\/1682904 (2020).","DOI":"10.1155\/2020\/1682904"},{"key":"44786_CR6","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","volume":"37","author":"H Taheri","year":"2020","unstructured":"Taheri, H. et al. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv. Ther. 37, 4697\u20134708. https:\/\/doi.org\/10.1007\/s12325-020-01498-5 (2020).","journal-title":"Adv. Ther."},{"key":"44786_CR7","doi-asserted-by":"publisher","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin, J. et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. Bmj 389, e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735 (2025).","journal-title":"Bmj"},{"key":"44786_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","volume":"43","author":"S Kahl","year":"2020","unstructured":"Kahl, S. et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 43, 298\u2013305. https:\/\/doi.org\/10.2337\/dc19-0641 (2020).","journal-title":"Diabetes Care"},{"key":"44786_CR9","doi-asserted-by":"publisher","first-page":"103751","DOI":"10.1016\/j.drudis.2023.103751","volume":"28","author":"G Astarita","year":"2023","unstructured":"Astarita, G., Kelly, R. S. & Lasky-Su, J. Metabolomics and lipidomics strategies in modern drug discovery and development. Drug Discov Today. 28, 103751. https:\/\/doi.org\/10.1016\/j.drudis.2023.103751 (2023).","journal-title":"Drug Discov Today"},{"key":"44786_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.17179\/excli2022-5482","volume":"22","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T. & Sahebkar, A. Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. Excli j. 22, 53\u201366. https:\/\/doi.org\/10.17179\/excli2022-5482 (2023).","journal-title":"Excli j."},{"key":"44786_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco, H., Voorrips, S. N., Yurista, S. R., de Boer, R. A. & Westenbrink, B. D. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. J. Lipid Atheroscler. 11, 1\u201319. https:\/\/doi.org\/10.12997\/jla.2022.11.1.1 (2022).","journal-title":"J. Lipid Atheroscler"},{"key":"44786_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5152\/eurjrheum.2023.23062","volume":"10","author":"\u00c7 Y\u00fccel","year":"2023","unstructured":"Y\u00fccel, \u00c7. et al. Comparative Metabolomic Profiles of Vascular Involvement in Beh\u00e7et\u2019s Disease. Eur. J. Rheumatol. 10, 130\u2013135. https:\/\/doi.org\/10.5152\/eurjrheum.2023.23062 (2023).","journal-title":"Eur. J. Rheumatol."},{"key":"44786_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"44786_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/08465371221123696","volume":"74","author":"HN \u015eendur","year":"2023","unstructured":"\u015eendur, H. N. et al. Hepatic Fat Quantification With Novel Ultrasound Based Techniques: A Diagnostic Performance Study Using Magnetic Resonance Imaging Proton Density Fat Fraction as Reference Standard. Can. Assoc. Radiol. J. 74, 362\u2013369. https:\/\/doi.org\/10.1177\/08465371221123696 (2023).","journal-title":"Can. Assoc. Radiol. J."},{"key":"44786_CR15","doi-asserted-by":"publisher","first-page":"15235","DOI":"10.1038\/s41598-023-42463-w","volume":"13","author":"SK Jeon","year":"2023","unstructured":"Jeon, S. K. et al. Development and validation of multivariable quantitative ultrasound for diagnosing hepatic steatosis. Sci. Rep. 13, 15235. https:\/\/doi.org\/10.1038\/s41598-023-42463-w (2023).","journal-title":"Sci. Rep."},{"key":"44786_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.dld.2021.08.017","volume":"54","author":"M Mo","year":"2022","unstructured":"Mo, M., Huang, Z., Liang, Y., Liao, Y. & Xia, N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig. Liver Dis. 54, 461\u2013468. https:\/\/doi.org\/10.1016\/j.dld.2021.08.017 (2022).","journal-title":"Dig. Liver Dis."},{"key":"44786_CR17","doi-asserted-by":"publisher","first-page":"603837","DOI":"10.3389\/fcell.2020.603837","volume":"8","author":"Z Wei","year":"2020","unstructured":"Wei, Z., Liu, X., Cheng, C., Yu, W. & Yi, P. Metabolism of Amino Acids in Cancer. Front. Cell. Dev. Biol. 8, 603837. https:\/\/doi.org\/10.3389\/fcell.2020.603837 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"key":"44786_CR18","doi-asserted-by":"publisher","first-page":"1501305","DOI":"10.3389\/fendo.2025.1501305","volume":"16","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. Clinical metabolomics in type 2 diabetes mellitus: from pathogenesis to biomarkers. Front. Endocrinol. (Lausanne). 16, 1501305. https:\/\/doi.org\/10.3389\/fendo.2025.1501305 (2025).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"44786_CR19","doi-asserted-by":"publisher","first-page":"109781","DOI":"10.1016\/j.diabres.2022.109781","volume":"186","author":"K Horibe","year":"2022","unstructured":"Horibe, K. et al. Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese patients with type 2 diabetes treated by oral anti-diabetic agents: A randomized, clinical trial. Diabetes Res. Clin. Pract. 186, 109781. https:\/\/doi.org\/10.1016\/j.diabres.2022.109781 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"44786_CR20","doi-asserted-by":"publisher","first-page":"104342","DOI":"10.1016\/j.ebiom.2022.104342","volume":"86","author":"F Furuya","year":"2022","unstructured":"Furuya, F. et al. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. EBioMedicine 86, 104342. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104342 (2022).","journal-title":"EBioMedicine"},{"key":"44786_CR21","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1073\/pnas.0802862105","volume":"105","author":"SG Park","year":"2008","unstructured":"Park, S. G., Schimmel, P. & Kim, S. Aminoacyl tRNA synthetases and their connections to disease. Proc. Natl. Acad. Sci. U S A. 105, 11043\u201311049. https:\/\/doi.org\/10.1073\/pnas.0802862105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"44786_CR22","doi-asserted-by":"publisher","first-page":"102630","DOI":"10.1016\/j.redox.2023.102630","volume":"61","author":"I L\u00f3pez-Soldado","year":"2023","unstructured":"L\u00f3pez-Soldado, I. et al. Decreased expression of mitochondrial aminoacyl-tRNA synthetases causes downregulation of OXPHOS subunits in type 2 diabetic muscle. Redox Biol. 61, 102630. https:\/\/doi.org\/10.1016\/j.redox.2023.102630 (2023).","journal-title":"Redox Biol."},{"key":"44786_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12944-017-0594-3","volume":"16","author":"M Femlak","year":"2017","unstructured":"Femlak, M., Gluba-Brz\u00f3zka, A., Cia\u0142kowska-Rysz, A. & Rysz, J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 16, 207. https:\/\/doi.org\/10.1186\/s12944-017-0594-3 (2017).","journal-title":"Lipids Health Dis."},{"key":"44786_CR24","doi-asserted-by":"publisher","first-page":"e1356518","DOI":"10.1080\/19381980.2017.1356518","volume":"9","author":"Y Mirdamadi","year":"2017","unstructured":"Mirdamadi, Y. et al. Insulin and Insulin-like growth factor-1 can activate the phosphoinositide-3-kinase \/Akt\/FoxO1 pathway in T cells in vitro. Dermatoendocrinol 9, e1356518. https:\/\/doi.org\/10.1080\/19381980.2017.1356518 (2017).","journal-title":"Dermatoendocrinol"},{"key":"44786_CR25","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.drudis.2022.02.006","volume":"27","author":"A Ahmadi","year":"2022","unstructured":"Ahmadi, A., Bagheri Ekta, M. & Sahebkar, A. Mechanisms of antidiabetic drugs and cholesterol efflux: A clinical perspective. Drug Discov Today. 27, 1679\u20131688. https:\/\/doi.org\/10.1016\/j.drudis.2022.02.006 (2022).","journal-title":"Drug Discov Today"},{"key":"44786_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12967-022-03629-8","volume":"20","author":"YP Lu","year":"2022","unstructured":"Lu, Y. P. et al. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J. Transl Med. 20, 420. https:\/\/doi.org\/10.1186\/s12967-022-03629-8 (2022).","journal-title":"J. Transl Med."},{"key":"44786_CR27","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.2337\/dc18-0840","volume":"41","author":"C Razquin","year":"2018","unstructured":"Razquin, C. et al. Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial. Diabetes Care. 41, 2617\u20132624. https:\/\/doi.org\/10.2337\/dc18-0840 (2018).","journal-title":"Diabetes Care"},{"key":"44786_CR28","doi-asserted-by":"publisher","first-page":"1065665","DOI":"10.3389\/fendo.2022.1065665","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Integrated lipids biomarker of the prediabetes and type 2 diabetes mellitus Chinese patients. Front. Endocrinol. (Lausanne). 13, 1065665. https:\/\/doi.org\/10.3389\/fendo.2022.1065665 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"44786_CR29","doi-asserted-by":"publisher","first-page":"46658","DOI":"10.1038\/srep46658","volume":"7","author":"F Chiappini","year":"2017","unstructured":"Chiappini, F. et al. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci. Rep. 7, 46658. https:\/\/doi.org\/10.1038\/srep46658 (2017).","journal-title":"Sci. Rep."},{"key":"44786_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12933-023-01933-1","volume":"22","author":"A Villasanta-Gonzalez","year":"2023","unstructured":"Villasanta-Gonzalez, A. et al. Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study. Cardiovasc. Diabetol. 22, 199. https:\/\/doi.org\/10.1186\/s12933-023-01933-1 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"44786_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1194\/jlr.M700184-JLR200","volume":"49","author":"MS Han","year":"2008","unstructured":"Han, M. S. et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J. Lipid Res. 49, 84\u201397. https:\/\/doi.org\/10.1194\/jlr.M700184-JLR200 (2008).","journal-title":"J. Lipid Res."},{"key":"44786_CR32","doi-asserted-by":"publisher","unstructured":"Shabalala, S. C. et al. Detrimental Effects of Lipid Peroxidation in Type 2 Diabetes: Exploring the Neutralizing Influence of Antioxidants. Antioxid. (Basel). 11 https:\/\/doi.org\/10.3390\/antiox11102071 (2022).","DOI":"10.3390\/antiox11102071"},{"key":"44786_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1053\/meta.2002.35202","volume":"51","author":"JN Clore","year":"2002","unstructured":"Clore, J. N., Allred, J., White, D., Li, J. & Stillman, J. The role of plasma fatty acid composition in endogenous glucose production in patients with type 2 diabetes mellitus. Metabolism 51, 1471\u20131477. https:\/\/doi.org\/10.1053\/meta.2002.35202 (2002).","journal-title":"Metabolism"},{"key":"44786_CR34","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1038\/srep05832","volume":"4","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci. Rep. 4, 5832. https:\/\/doi.org\/10.1038\/srep05832 (2014).","journal-title":"Sci. Rep."},{"key":"44786_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.advms.2022.06.001","volume":"67","author":"E Soko\u0142owska","year":"2022","unstructured":"Soko\u0142owska, E. et al. Sphingomyelin profiling in patients with diabetes could be potentially useful as differential diagnostics biomarker: A pilot study. Adv. Med. Sci. 67, 250\u2013256. https:\/\/doi.org\/10.1016\/j.advms.2022.06.001 (2022).","journal-title":"Adv. Med. Sci."},{"key":"44786_CR36","doi-asserted-by":"publisher","first-page":"e0213285","DOI":"10.1371\/journal.pone.0213285","volume":"14","author":"SS Im","year":"2019","unstructured":"Im, S. S. et al. Plasma sphingomyelins increase in pre-diabetic Korean men with abdominal obesity. PLoS One. 14, e0213285. https:\/\/doi.org\/10.1371\/journal.pone.0213285 (2019).","journal-title":"PLoS One"},{"key":"44786_CR37","doi-asserted-by":"publisher","unstructured":"Simon, J. et al. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21010040 (2019).","DOI":"10.3390\/ijms21010040"},{"key":"44786_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1248\/bpb.b15-00060","volume":"38","author":"YK Kaneko","year":"2015","unstructured":"Kaneko, Y. K. & Ishikawa, T. Diacylglycerol Signaling Pathway in Pancreatic \u03b2-Cells: An Essential Role of Diacylglycerol Kinase in the Regulation of Insulin Secretion. Biol. Pharm. Bull. 38, 669\u2013673. https:\/\/doi.org\/10.1248\/bpb.b15-00060 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"44786_CR39","doi-asserted-by":"publisher","first-page":"e22775","DOI":"10.1371\/journal.pone.0022775","volume":"6","author":"DL Gorden","year":"2011","unstructured":"Gorden, D. L. et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One. 6, e22775. https:\/\/doi.org\/10.1371\/journal.pone.0022775 (2011).","journal-title":"PLoS One"},{"key":"44786_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s13238-017-0423-5","volume":"9","author":"JM Dean","year":"2018","unstructured":"Dean, J. M. & Lodhi, I. J. Structural and functional roles of ether lipids. Protein Cell. 9, 196\u2013206. https:\/\/doi.org\/10.1007\/s13238-017-0423-5 (2018).","journal-title":"Protein Cell."},{"key":"44786_CR41","doi-asserted-by":"publisher","unstructured":"Lair, B., Laurens, C., Van Den Bosch, B. & Moro, C. Novel Insights and Mechanisms of Lipotoxicity-Driven Insulin Resistance. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21176358 (2020).","DOI":"10.3390\/ijms21176358"},{"key":"44786_CR42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","volume":"50","author":"G Ferraioli","year":"2024","unstructured":"Ferraioli, G. et al. WFUMB Guideline\/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography. Ultrasound. Med. Biol. 50, 1071\u20131087. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2024.03.013 (2024).","journal-title":"Ultrasound. Med. Biol."},{"key":"44786_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/jum.16048","volume":"42","author":"HN \u015eendur","year":"2023","unstructured":"\u015eendur, H. N., Cerit, M. N., Ibrahimkhanli, N. & \u015eendur, A. B. \u00d6zhan Oktar, S. Interobserver Variability in Ultrasound-Based Liver Fat Quantification. J. Ultrasound Med. 42, 833\u2013841. https:\/\/doi.org\/10.1002\/jum.16048 (2023).","journal-title":"J. Ultrasound Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44786-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:18:00Z","timestamp":1783034280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44786-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44786"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44786-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20421"}}